HDAC9 and AL amyloidosis: In addition, three other HDAC inhibitors have been approved by the FDA, romidepsin, belinostat and panobinostat, which have primarily been used in multiple myeloma, peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma.117